Loestrin transaction gets further FTC scrutiny
Executive Summary
FTC has requested additional information on Barr's proposed acquisition of rights to Galen's Loestrin oral contraceptive line (1"The Pink Sheet" Sept. 15, 2003, p. 37). Barr had hoped to close the deal by Feb. 1; the company is "unable to determine the impact" of FTC's request for additional information...
You may also be interested in...
Galen Settles Estrostep, FemHRT Litigation, Barr Picks Up Loestrin In Deal
A product licensing agreement between Galen and Barr will settle FemHRT and Estrostep patent litigation inherited by Galen from Pfizer
Kenvue Breaks Ground On New Headquarters, Appoints Chief Corporate Affairs Officer
Firm hosts groundbreaking for 290,000 square-foot global headquarters it’s having built in Summit, NJ, starting with 100,000 square-foot science and innovation and expected to open in 2025. It announced adding Russell Dyer as chief corporate affairs officer starting 13 March.
Xaira Launches With $1bn-Plus And End-To-End AI Strategy
ARCH and Foresite incubated the company and recruited Genentech R&D veteran Marc Tessier-Lavigne to keep data generation, machine learning research and drug development under one roof.